Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

NCT06981325 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
34
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators